-
Better Buy: Johnson & Johnson vs. AbbVie
Post on 1/30/17
-
3 Reasons to Buy Pfizer Stock and Never Sell
Post on 1/30/17
-
Johnson & Johnson May Never Recoup Its Costs to Buy Actelion
Post on 1/30/17
-
The Valley Hospital Unveils Plan to Relocate and Build New Hospital
Post on 1/29/17
-
The Endoscopy Center at St. Mary Partners with Physicians Endoscopy
Post on 1/29/17
-
Is GlaxoSmithKline's Dividend Sustainable?
Post on 1/27/17
-
Johnson & Johnson's Foolishness Is on Full Display
Post on 1/27/17
-
Johnson & Johnson's Most Exciting Opportunity
Post on 1/27/17
-
Celgene's Fastest-Growing Drugs
Post on 1/27/17
-
Quest Diagnostics Partners With Montefiore Health System
Post on 1/26/17
-
How Bad Were Johnson & Johnson's Results?
Post on 1/26/17
-
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Post on 1/26/17
-
3 Top Biotech Stocks to Buy Now
Post on 1/26/17
-
Johnson & Johnson's 2017 Guidance Disappoints -- Could This Be the Issue?
Post on 1/26/17
-
Enteris BioPharma Enters into Agreement with Nordic Bioscience's KeyBioscience
Post on 1/25/17
-
SOTA Medical Products and SafeOp Surgical Ink Distribution Agreement
Post on 1/25/17
-
Johnson & Johnson: Buy The Dip?
Post on 1/25/17
-
Johnson & Johnson Opens 2017 on a Cautious Note
Post on 1/25/17
-
How Will Johnson & Johnson Fare Under President Trump?
Post on 1/25/17
-
Uh-Oh: This Could Be Johnson & Johnson's Biggest Risk in 2017
Post on 1/25/17
-
Immunomedics Mails Letter to Stockholders
Post on 1/24/17
-
10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report
Post on 1/24/17
-
Better Buy: Exelixis, Inc. vs. Novartis
Post on 1/24/17
-
Enteris BioPharma Enters Agreement with Sanofi
Post on 1/23/17
-
Recovery Centers of America Opens Boston Center for Addiction Treatment
Post on 1/23/17
Philadelphia
